Skip to main content
Premium Trial:

Request an Annual Quote

Lentigen

Premium

Lentigen Licenses ZGene Technology

Lentigen said this week that it has taken an exclusive license from ZGene to certain specified proprietary ZGene multisubstrate kinase genes for certain indications.

These genes will allow Lentigen to create lentiviral vectors with increased safety by providing the capability to eliminate genetically modified cells from the body, if required, the company said.

ZGene will receive an undisclosed upfront payment and stands to receive milestones based on development and commercialization goals, as well as royalties. Additional terms of the deal were not disclosed.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.